COMPARison of pre-hospital CRUSHed vs. uncrushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary interventions - Compare Crush

Research Maatschap Cardiologen Rotterdam Zuid0 个研究点目标入组 729 人开始时间: 待定最近更新: 2024年4月23日

适应症

试验速览

Trial is onging in other countries

•- Contraindication to prasugrel (e.g., hypersensitivity, active bleeding,
•history of previous intracranial bleed, history of any CVA, including TIA,
•moderate to severe hepatic impairment, GI bleed within the past 6 months, major
•surgery within past 4 weeks)
•- Patient who has received loading dose of Clopidogrel or ticagrelor for the
•index event or are on chronic treatment of ticagrelor. However, patients on
•maintenance dose clopidogrel for at least 7 days are included in the study. See
•appendix A (patient on clopidogrel maintenance dose)
•- Oral anticoagulation therapy that cannot be stopped (i.e. patients requiring
•chronic therapy)
•- Planned fibrinolytic treatment
•- Patient requiring dialysis
•- Known, clinically important thrombocytopenia
•- Known clinically important anaemia
•- Known pregnancy or lactation
•- Need for a concomitant systemic therapy with strong inhibitors or strong
•inducers of CYP3A
•- Condition which may either put the patient at risk or influence the result of
•the study (e.g., cardiogenic shock or severe hemodynamic instability, active
•cancer, risk for non-compliance, risk for being lost to follow up)
•- Patient unable to swallow oral medication (i.e. intubated patients)

发起方

Research Maatschap Cardiologen Rotterdam Zuid